SCHEMBL30504899

SCHEMBL30504899

CO[C@@H]1CCN(C2CCC(NC(=O)OC(C)(C)C)CC2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 2/20 0.47
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ BTK Q06187 1/20 0.41
▸ HSD11B1 P28845 3/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ DRD2 P14416 4/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ OGFRL1 Q5TC84 1/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ CCRL2 O00421 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13036669 0.86 CTSK (0.49) CTSKCA1CA2BTKHSD11B1
SCHEMBL30504919 0.84 CTSK (0.49) CTSKCA1CA2BTKHSD11B1
SCHEMBL17207638 0.84 CTSK (0.49) CTSKCA1CA2BTKHSD11B1
SCHEMBL30504918 0.84 CTSK (0.49) CTSKCA1CA2BTKHSD11B1
SCHEMBL17207727 0.84 CTSK (0.49) CTSKCA1CA2BTKHSD11B1
SCHEMBL1699916 0.83 CTSK (0.61) CTSKCA1CA2BTKHSD11B1
SCHEMBL1699915 0.83 CTSK (0.61) CTSKCA1CA2BTKHSD11B1
SCHEMBL1808105 0.83 CTSK (0.61) CTSKCA1CA2BTKHSD11B1
SCHEMBL12794288 0.83 CTSK (0.52) CTSKCA1CA2BTKHSD11B1
SCHEMBL12794285 0.83 CTSK (0.52) CTSKCA1CA2BTKHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023159322-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2023-08-31 — — WO disclosed
Send feedback